共 140 条
[1]
Zhang X(2017)The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway Biomed Pharmacother 91 1042-1052
[2]
Du Q(2020)Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis Acta Pharmacol Sin 41 319-327
[3]
Yang Y(2017)Antiinflammatory therapy with canakinumab for atherosclerotic disease N Engl J Med 377 1119-1131
[4]
Bian Y(2019)Low-dose methotrexate for the prevention of atherosclerotic events N Engl J Med 380 752-762
[5]
Li X(2019)Efficacy and safety of low-dose colchicine after myocardial Infarction N Engl J Med 381 2497-2505
[6]
Pang P(2020)Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) Eur Heart J 41 4092-4097
[7]
Ridker PM(2012)Doxil® - The first FDA-approved nano-drug: Lessons learned J Control Release 160 117-134
[8]
Everett BM(1994)Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 987-992
[9]
Thuren T(2001)Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312-3322
[10]
Ridker PM(2007)Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann Oncol 18 716-721